Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2006 | Original Paper

Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt’s lymphoma cells

Authors: Mei Hong, Yoshihiro Murai, Tomohiko Kutsuna, Hiroyuki Takahashi, Kazuhiro Nomoto, Chun-Mei Cheng, Shin Ishizawa, Qing-Li Zhao, Ryohei Ogawa, Brian V. Harmon, Koichi Tsuneyama, Yasuo Takano

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2006

Abstract

Purpose: Epstein-Barr virus (EBV) is associated with the development of several lymphoid and epithelial malignancies, including Burkitt’s lymphoma. The EBV latent protein, EBV Nuclear Antigen 1 (EBNA1), is detectable in almost all types of EBV-associated tumors and is essential for replication and maintenance of the latent episome of EBV. We here examined whether the RNA interference (RNAi) technique could be employed to suppress expression of EBNA1 in EBV-positive Burkitt’s lymphoma cells. Methods: A Raji cell line expressing small hairpin RNAs (shRNAs) against EBNA1 was established and EBNA1 mRNA level was determined by real-time RT-PCR analysis. We investigated the effects of EBNA1 silence on lymphoma cell growth and cell cycle progression. Results: Transfection of an EBNA1 RNAi plasmid resulted in substantial loss of EBNA1 mRNA and significantly inhibited proliferation of Raji cells relative to the control plasmid case. Suppression of EBNA1 was also associated with downregulation of EBV oncogene EBNA2, a decreased PCNA labeling index and increased G0/G1 fraction in cell cycle analysis. Conclusions: These findings point to potential therapeutic applications for vector-mediated siRNA delivery to control EBV-associated malignant disorders.

Adams A (1987) Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 61:1743–1746PubMed

Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553CrossRefPubMed

Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, Hoppe-Seyler F (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22:5938–5945CrossRefPubMed

Chen MR, Middeldorp JM, Hayward SD (1993) Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol 67:4875–4885PubMed

Davenport MG, Pagano JS (1999) Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J Virol 73:3154–3161PubMed

de la Luna S, Ortin J (1992) pac gene as efficient dominant marker and reporter gene in mammalian cells. Methods Enzymol 216:376–385PubMedCrossRef

Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457–467CrossRefPubMed

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498CrossRefPubMed

Gahn TA, Sugden B (1995) An EBNA-1-dependent enhancer acts from a distance of ten kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 69:2633–2636PubMed

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed

Grasser FA, Murray PG, Kremmer E, Klein K, Remberger K, Feiden W, Reynolds G, Niedobitek G, Young LS, Mueller-Lantzsch N (1994) Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin’s disease. Blood 84:3792–3798PubMed

Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB (1999) Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma reflect virus strains prevalent in different geographic areas. J Virol 73:965–975PubMed

Hall AH, Alexander KA (2003) RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 77:6066–6069CrossRefPubMed

Hannon GJ, Rossi JJ (2004) Unlocking the potential of the human genome with RNA interference. Nature 431:371–378CrossRefPubMed

Hatfull G, Bankier AT, Barrell BG, Farrell PJ (1988) Sequence analysis of Raji Epstein-Barr virus DNA. Virology 164:334–340CrossRefPubMed

Heller M, van Santen V, Kieff E (1982) Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol 44:311–320PubMed

Huang S, Stupack D, Mathias P, Wang Y, Nemerow G (1997) Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc Natl Acad Sci USA 94:8156–8161CrossRefPubMed

Hung SC, Kang MS, Kieff E (2001) Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci USA 98:1865–1870CrossRefPubMed

Isaksson A, Berggren M, Ricksten A (2003) Epstein-Barr virus U leader exon contains an internal ribosome entry site. Oncogene 22:572–581CrossRefPubMed

Israel BF, Kenney SC (2003) Virally targeted therapies for EBV-associated malignancies. Oncogene 22:5122–5130CrossRefPubMed

Jiang M, Milner J (2002) Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21:6041–6048CrossRefPubMed

Kenney JL, Guinness ME, Curiel T, Lacy J (1998) Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 92:1721–1727PubMed

Kieff E (1996) Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 3rd edn, vol 2. Lippincott-Raven Publishers, Philadelphia, pp 2343–2396

Knudsen ES, Wang JY (1997) Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17:5771–5783PubMed

Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y (2004) Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17:1141–1149CrossRefPubMed

Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685–688CrossRefPubMed

Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94:12616–12621CrossRefPubMed

Li XP, Li G, Peng Y, Kung HF, Lin MC (2004) Suppression of Epstein-Barr virus-encoded latent membrane protein-1 by RNA interference inhibits the metastatic potential of nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 315:212–218CrossRefPubMed

Marechal V, Dehee A, Chikhi-Brachet R, Piolot T, Coppey-Moisan M, Nicolas JC (1999) Mapping EBNA-1 domains involved in binding to metaphase chromosomes. J Virol 73:4385–4392PubMed

Mathews MB, Bernstein RM, Franza BR Jr, Garrels JI (1984) Identity of the proliferating cell nuclear antigen and cyclin. Nature 309:374–376CrossRefPubMed

Mattia E, Chichiarelli S, Hickish T, Gaeta A, Mancini C, Cunningham D, van Renswoude J (1997) Inhibition of in vitro proliferation of Epstein-Barr virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. Oncogene 15:489–493CrossRefPubMed

Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ (2003) Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 45:1–36PubMedCrossRef

Polack A, Delius H, Zimber U, Bornkamm GW (1984) Two deletions in the Epstein-Barr virus genome of the Burkitt lymphoma nonproducer line Raji. Virology 133:146–157CrossRefPubMed

Randall G, Grakoui A, Rice CM (2003) Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 100:235–240CrossRefPubMed

Reisman D, Yates J, Sugden B (1985) A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 5:1822–1832PubMed

Roth G, Curiel T, Lacy J (1994) Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84:582–587PubMed

Sample J, Hummel M, Braun D, Birkenbach M, Kieff E (1986) Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci USA 83:5096–5100PubMedCrossRef

Sample J, Brooks L, Sample C, Young L, Rowe M, Gregory C, Rickinson A, Kieff E (1991) Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci USA 88:6343–6347PubMedCrossRef

Schepers A, Ritzi M, Bousset K, Kremmer E, Yates JL, Harwood J, Diffley JF, Hammerschmidt W (2001) Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J 20:4588–4602CrossRefPubMed

Sugden B, Warren N (1989) A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 63:2644–2649PubMed

Sugimoto M, Tahara H, Ide T, Furuichi Y (2004) Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res 64:3361–3364CrossRefPubMed

Sung NS, Wilson J, Davenport M, Sista ND, Pagano JS (1994) Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Mol Cell Biol 14:7144–7152PubMed

Tomar RS, Matta H, Chaudhary PM (2003) Use of adeno-associated viral vectors for delivery of small interfering RNA. Oncogene 22:5712–5715CrossRefPubMed

Wilson JB, Bell JL, Levine AJ (1996) Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15:3117–3126PubMed

Yates J, Warren N, Reisman D, Sugden B (1984) A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81:3806–3810PubMedCrossRef

Yates JL, Guan N (1991) Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 65:483–488PubMed

Yates JL, Warren N, Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313:812–815CrossRefPubMed

Young LS, Murray PG (2003) Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22:5108–5121CrossRefPubMed

Zhang D, Frappier L, Gibbs E, Hurwitz J, O’Donnell M (1998) Human RPA (hSSB) interacts with EBNA1, the latent origin binding protein of Epstein-Barr virus. Nucleic Acids Res 26:631–637CrossRefPubMed

Title: Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt’s lymphoma cells
Authors: Mei Hong
Yoshihiro Murai
Tomohiko Kutsuna
Hiroyuki Takahashi
Kazuhiro Nomoto
Chun-Mei Cheng
Shin Ishizawa
Qing-Li Zhao
Ryohei Ogawa
Brian V. Harmon
Koichi Tsuneyama
Yasuo Takano
Publication date: 01-01-2006
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2006
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-005-0036-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Cancer-associated loss of TARSH gene expression in human primary lung cancer

Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis

Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer

Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS)

Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor

Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials